Edition:
United Kingdom

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

23.24USD
12 Oct 2018
Change (% chg)

-- (--)
Prev Close
$23.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
266,098
52-wk High
$35.99
52-wk Low
$16.33

Latest Key Developments (Source: Significant Developments)

Intellia Therapeutics posts Q2 Results
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Intellia Therapeutics Inc ::INTELLIA THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.INTELLIA THERAPEUTICS INC - COLLABORATION REVENUE WAS $7.7 MILLION FOR Q2 OF 2018, COMPARED TO $5.9 MILLION.INTELLIA THERAPEUTICS INC - AS OF JUNE 30, 2018, COMPANY HAD AN ACCUMULATED DEFICIT OF $159.3 MILLION.INTELLIA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.52.  Full Article

Intellia Therapeutics, Regeneron Agreed To Co-Development Agreement
Friday, 20 Jul 2018 

July 20 (Reuters) - Intellia Therapeutics Inc ::INTELLIA THERAPEUTICS - CO, REGENERON AGREED TO CO-DEVELOPMENT/CO-PROMOTION AGREEMENT CONSISTENT WITH A CERTAIN SCHEDULE OF THEIR APRIL 2016 COLLABORATION DEAL.INTELLIA THERAPEUTICS SAYS CO, REGENERON ENTERED INTO FIRST CO-DEVELOPMENT/CO-PROMOTION AGREEMENT DIRECTED TO A TARGET, WHICH IS TRANSTHYRETIN - SEC FILING.  Full Article

Intellia Therapeutics Says CFO Informed Co He Will Be Resigning
Friday, 22 Jun 2018 

June 22 (Reuters) - Intellia Therapeutics Inc ::INTELLIA THERAPEUTICS - ON JUNE 18, GRAEME BELL, EXECUTIVE VICE PRESIDENT, CFO OF CO INFORMED HE WILL BE RESIGNING FROM HIS POSITION EFFECTIVE AUG 3.INTELLIA THERAPEUTICS - COMPANY HAS COMMENCED A FORMAL SEARCH FOR A NEW CHIEF FINANCIAL OFFICER - SEC FILING.  Full Article

Intellia Therapeutics Inc Q1 Loss Per Share $0.51
Tuesday, 1 May 2018 

May 1 (Reuters) - Intellia Therapeutics Inc ::INTELLIA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.ANTICIPATES SUBMITTING ITS IN VIVO INVESTIGATIONAL NEW DRUG APPLICATION BY END OF 2019.QTRLY LOSS PER SHARE $0.51.$328 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018.CONFIRMS PLANS TO INITIATE IND-ENABLING STUDIES IN MID-2018 FOR ITS LEAD INDICATION, TRANSTHYRETIN AMYLOIDOSIS.INTELLIA PLANS TO SHARE PRECLINICAL DATA ON BOTH IMMUNO-ONCOLOGY AND AUTOIMMUNE DISEASE TARGETS IN 2018.COLLABORATION REVENUE WAS $7.5 MILLION FOR Q1 OF 2018, COMPARED TO $6.2 MILLION DURING Q1 OF 2017.Q1 EARNINGS PER SHARE VIEW $-0.58, REVENUE VIEW $6.3 MILLION -- THOMSON REUTERS I/B/E/S.INTELLIA - EXPECTS CASH, CASH EQUIVALENTS AS OF MARCH 31, 2018 WILL ENABLE CO TO FUND OPERATING EXPENSES AND CAPEX THROUGH MID-2020.  Full Article

Intellia Therapeutics Reports Qtrly Net Loss Per Share $0.61
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Intellia Therapeutics Inc ::INTELLIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.COLLABORATION REVENUE WAS $6.7 MILLION FOR Q4 OF 2017, COMPARED TO $5.6 MILLION FOR Q4 OF PRIOR YEAR.QTRLY NET LOSS PER SHARE $0.61.Q4 EARNINGS PER SHARE VIEW $-0.42, REVENUE VIEW $8.6 MILLION -- THOMSON REUTERS I/B/E/S.INTELLIA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017, OTHER FUNDING WILL FUND OPERATING EXPENSES AND CAPEX THROUGH MID-2020.INTELLIA THERAPEUTICS - HAD ‍$341 MILLION IN CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017​.  Full Article

Intellia Therapeutics Names John Leonard, M.D., President And CEO
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Intellia Therapeutics Inc ::INTELLIA THERAPEUTICS NAMES JOHN LEONARD, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER.INTELLIA THERAPEUTICS INC - LEONARD SUCCEEDS NESSAN BERMINGHAM.  Full Article

Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Intellia Therapeutics Inc :Intellia Therapeutics announces pricing of public offering of common stock.Says ‍priced public offering of 6.3 million shares of its common stock at a public offering price of $24.00 per share​.  Full Article

Intellia Therapeutics announces proposed public offering of common stock
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Intellia Therapeutics Inc NTLA.O:Intellia therapeutics announces proposed public offering of common stock.Intellia therapeutics inc - ‍has commenced an underwritten public offering of $150 million of its common stock​.  Full Article

Intellia Therapeutics Q3 loss per share $‍0.44​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Intellia Therapeutics Inc ::Intellia therapeutics announces third quarter 2017 financial results.Q3 collaboration revenue $7.3 million versus $4.9 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/Cas9.Qtrly loss per share $‍0.44​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Intellia Therapeutics Q3 revenue $65 mln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Intellia Therapeutics Inc -:Intellia Therapeutics announces third quarter 2017 financial results.Q3 revenue $65 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/CAS9.  Full Article

UPDATE 2-U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing

Sept 10 A U.S. appeals court on Monday allowed a research center affiliated with the Massachusetts Institute of Technology and Harvard University to keep patents potentially worth billions of dollars on a groundbreaking gene editing technology known as CRISPR.